The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...

Shares of Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) gapped up before the market opened on Thursday following a better than expected earnings announcement. The stock had previously closed at ...

Pliant Therapeutics (PLRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

These compelling results support advancing the development of nintedanib DPI for patients living with IPF, a chronic and progressive fibrotic lung disease with limited treatment options,” said Michael ...

Walker announced earlier in the month that he was retiring from radio after 58 years due to ill health, having been previously diagnosed with idiopathic pulmonary fibrosis (IPF). After playing Johnny ...

Timely intervention in oncology is critical for improving survival rates, disease progression, and quality of life. Delays in treatment can result in advanced disease stages, reduced treatment ...

CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in a Phase 1 clinical trial, according to results announced by ...

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH ...

Insiders say Katie Price has been frantic with worry over an intense situation, but is keeping positive by focusing on her ...

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and ...

Interested parties may access the live audio webcast for each conference via the Investors section of the Surrozen website at https://investors.surrozen.com/events-presentations/events-calendar. A ...